Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 12/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | SNCA | P37840 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | INSR | P06213 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | ATP4A | P20648 | 1/20 | 0.43 |
| ▸ | ATP4B | P51164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30445749 | 0.84 | APP (0.61) | APPKDM4EMAPTINSRATP4A | |
| SCHEMBL6490502 | 0.84 | APP (0.61) | APPKDM4EMAPTINSRATP4A | |
| SCHEMBL10036021 | 0.81 | MEN1 (0.61) | APPKDM4EMAPTINSRMAPK1 | |
| SCHEMBL476616 | 0.81 | MEN1 (0.59) | APPKDM4ESNCAMAPTINSR | |
| SCHEMBL11136666 | 0.81 | INSR (0.51) | APPMAPTINSRALOX15ATP4A | |
| SCHEMBL476617 | 0.81 | MEN1 (0.59) | APPKDM4ESNCAMAPTINSR | |
| SCHEMBL29397958 | 0.81 | MEN1 (0.59) | APPKDM4ESNCAMAPTINSR | |
| SCHEMBL11136663 | 0.81 | INSR (0.51) | APPMAPTINSRALOX15ATP4A | |
| SCHEMBL28820824 | 0.80 | SNCA (0.61) | APPKDM4ESNCALMNATHRB | |
| SCHEMBL6493271 | 0.79 | INSR (0.47) | APPMAPTINSRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120035187-A1 | ANTI-NEURODEGENERATIVE DISEASE AGENT | KABUSHIKI KAISHA HAYASHIBARA SEIBUTSU KAGAKU KENKYUJO (JP) | 2012-02-09 | — | — | US | disclosed |
| US-20120035187-A1 | ANTI-NEURODEGENERATIVE DISEASE AGENT | KABUSHIKI KAISHA HAYASHIBARA SEIBUTSU KAGAKU KENKYUJO (JP) | 2012-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035187-A1 | ANTI-NEURODEGENERATIVE DISEASE AGENT | SNCA, PSEN1, CDR2 | APP 15/4885KDM4E 3242/4885SNCA 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.